SAM
ALXN

Shamrock Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Shamrock Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$10K Buy
+100
New +$11.3K 0.01% 209
2019
Q2 		– Sell
-100
Closed -$14K – 266
2019
Q1 		$14K Buy
+100
New +$12.4K 0.01% 192

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Shamrock Asset Management's ALXN Position: Q3 2019 in Review

Shamrock Asset Management opened a new position in Alexion Pharmaceuticals (ALXN) in Q3 2019: 100 shares worth $10K. The stake represents 0.01% of the portfolio and ranks #209 among its holdings. This is a return to the name: Shamrock Asset Management previously reported a position in ALXN as recently as Q1 2019.

Shamrock Asset Management first reported a position in ALXN in Q1 2019 and has held it in 2 quarters since. The position peaked at $14K in Q1 2019. 647 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

  • Shamrock Asset Management held 100 shares of Alexion Pharmaceuticals worth $10K as of Q3 2019.
  • Alexion Pharmaceuticals was a new Shamrock Asset Management position in Q3 2019.
  • Alexion Pharmaceuticals made up 0.01% of Shamrock Asset Management's portfolio in Q3 2019, its #209 holding.
  • Shamrock Asset Management first reported a position in Alexion Pharmaceuticals in Q1 2019 and has held it in 2 quarters since.
  • Shamrock Asset Management's Alexion Pharmaceuticals position peaked at $14K in Q1 2019.
  • 647 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Shamrock Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.